However, in the 52-week extension trial dual action of liraglutide and insulin degludec in type 2 diabetes (DUAL I), the authors studied the fluctuations in plasma glucose of the combination of insulin degludec and liraglutide (IDegLira) against each of its components separately. The gene discussed is INS; the disease is type 2 diabetes mellitus.